Recon Regulatory Top Stories Lipogems Announces Last Patient Enrolled in the U.S. FDA IDE Arise Study for the Treatment of Knee Osteoarthritis byTim AllenApril 10, 2024
Recon Regulatory Top Stories Lipogems Announces First Patient Enrolled in the Second U.S. FDA IDE Study for the Treatment of Knee Osteoarthritis byTim AllenApril 8, 2024
Biologics Regulatory U.S. FDA Grants Lipogems® Second IDE Approval For A Clinical Trial On The Treatment For Knee OA byJosh SandbergOctober 4, 2023
Financial Top Stories Lipogems Raises €12.5M ($13.2M) to Accelerate the Expansion in Knee Osteoarthritis byJosh SandbergDecember 26, 2022
Biologics Extremities Regulatory Lipogems® Receives IDE Approval From The U.S. FDA To Begin A Pivotal Clinical Study On The Safety And Effectiveness Of The Lipogems System For The Treatment of Knee Osteoarthritis byChris StewartJune 10, 2022
Biologics Lipogems Provides Orthopaedic Patients With Another Option To Major Invasive Surgery byJosh SandbergJanuary 14, 2019
Hospitals FDA Clears The Way: Lipogems’ Receives FDA Clearance For Microfragmented Adipose Tissue System Utilizing Body’s Own Fat To Support Tissue Repair In Orthopaedic And Arthroscopic Surgeries byJosh SandbergJuly 6, 2018
